Stocks and Investing Stocks and Investing
Thu, April 22, 2021
Wed, April 21, 2021

David Lewis Maintained (ABT) at Buy with Increased Target to $140 on, Apr 21st, 2021


Published on 2024-10-27 16:20:05 - WOPRAI, David Lewis
  Print publication without navigation


David Lewis of Morgan Stanley, Maintained "Abbott Laboratories" (ABT) at Buy with Increased Target from $136 to $140 on, Apr 21st, 2021.

David has made no other calls on ABT in the last 4 months.



There are 8 other peers that have a rating on ABT. Out of the 8 peers that are also analyzing ABT, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • James Mainwaring of "Atlantic Equities" Initiated at Hold and Held Target at $122 on, Thursday, April 15th, 2021
  • Danielle Antalffy of "SVB Leerink" Maintained at Hold with Decreased Target to $115 on, Saturday, February 6th, 2021


These are the ratings of the 6 analyists that currently disagree with David


  • Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $130 on, Thursday, March 11th, 2021
  • Bob Hopkins of "B of A Securities" Maintained at Strong Buy with Increased Target to $145 on, Thursday, January 28th, 2021
  • Joshua Jennings of "Cowen & Co." Maintained at Buy with Increased Target to $140 on, Thursday, January 28th, 2021
  • Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $137 on, Thursday, January 28th, 2021
  • Marie Thibault of "BTIG" Upgraded from Hold to Strong Buy and Held Target at $140 on, Thursday, January 28th, 2021
  • Matt Miksic of "Credit Suisse" Maintained at Buy with Increased Target to $130 on, Thursday, January 28th, 2021
Contributing Sources